-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 17, Friendship Bio-PD-L/TGF-β double antibody Y101D was approved by clinical tacit approval, and its indications are locally advanced or metastatic tumors
.
It is understood that this is the fourth bispecific antibody new drug developed by Friends of Zhiyou after M802, M701 and Y150
.
Immunotherapy is one of the most promising treatment methods for tumors
.
PD-1/PD-L1 monoclonal antibody has attracted much attention because of its broad anti-cancer spectrum, long-lasting efficacy, and easy tolerability of side effects, but its response rate is limited to about 20% of tumor patients
.